---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-196465"
form_type: "8-K"
ticker: "APLS"
cik: "0001492422"
company_name: "Apellis Pharmaceuticals, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T10:49:43.492690+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Apellis/Sobi Phase 3 VALIANT meets primary endpoint; 68% proteinuria reduction in C3G/IC-MPGN

## Summary
- Statistically significant 68% proteinuria reduction vs placebo (p<0.0001) at Week 26.
- Key secondary endpoints met: composite renal endpoint and ≥50% proteinuria reduction.
- Favorable safety profile; no meningitis or serious infections from encapsulated bacteria.
- All VALIANT completers enrolled in long-term extension study VALE.
- Apellis to file sNDA with FDA in early 2025; Sobi to submit EMA application in 2025.

## SEC filing metadata
- accession: 0001193125-24-196465
- form_type: 8-K
- ticker: APLS
- cik: 0001492422
- company_name: Apellis Pharmaceuticals, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1492422/000119312524196465/0001193125-24-196465-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1492422/000119312524196465/d848612d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-196465
- JSON: https://secwatch.observer/filing/0001193125-24-196465.json
- Plain text: https://secwatch.observer/filing/0001193125-24-196465.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.